Core Insights - Henry Schein, Inc.'s joint venture, Henry Schein One, is experiencing strong growth in core products and new solutions, supported by a robust partnership strategy [1][3] - The company has faced headwinds from a sluggish macroeconomic environment and intense competition, which may impact operations [1][10] Financial Performance - Over the past year, Henry Schein's stock has increased by 6.4%, while the industry grew by 7.7% and the S&P 500 composite rose by 17.6% [2] - The company has a market capitalization of $8.29 billion and has beaten earnings estimates in three of the last four quarters, with an average surprise of 2.1% [2] Growth Drivers - Henry Schein One is benefiting from the adoption of cloud-based practice management software, with over 11,000 customers subscribed to its solutions [3] - A new partnership with Amazon Web Services will integrate generative AI technologies into the Henry Schein One ecosystem, enhancing AI-powered dentistry [4] - The introduction of LinkIt provides a seamless digital workflow for dental teams, connecting various digital imaging and planning systems [5] Expansion Strategies - The company has expanded its revenue growth through niche acquisitions and partnerships, including becoming the exclusive U.S. distributor for vVARDIS's Curodont Repair Fluoride Plus product [6] - A strategic partnership with Oral Genome aims to distribute innovative saliva testing solutions nationwide [7] - The acquisition of Acentus enhances Henry Schein's homecare medical products platform, while the acquisition of R. Weinstein, Inc. expands its presence in Hawaii [8] Challenges - The macroeconomic environment, including exchange rate fluctuations, inflation, and recession, is negatively impacting Henry Schein's financial operations [10] - The company's gross margin contracted by 19 basis points due to an 8% rise in the cost of sales, and SG&A expenses increased by 9.5% to $808 million [11] - The competitive landscape in the healthcare products distribution industry is intense, affecting market share and operational results [12] Future Outlook - The Zacks Consensus Estimate for Henry Schein's 2026 earnings per share has increased by 3 cents to $5.30, with revenues projected to rise by 3.9% to $13.70 billion [13]

Core Insights - Henry Schein One has launched the next era of Dentrix Ascend, introducing three new packages aimed at enhancing revenue and growth for dental practices and Dental Service Organizations (DSOs) [1] - The new offerings are built on an integrated platform that combines practice management, clinical workflows, imaging, and revenue cycle management, reflecting a shift from legacy systems to modern cloud platforms [1] Product Innovations - The new packages include advanced features such as Voice Notes, Image Verify, Eligibility Pro, and Digital Forms, which leverage AI to streamline operations and reduce administrative burdens [1] - Voice Notes uses generative AI to convert conversations into structured clinical records, while Image Verify assesses clinical images at capture to prevent claim denials [1] - Eligibility Pro performs real-time benefits checks, completing 191 million checks in 2025, and Digital Forms captures insurance data from images, with 22 million forms completed in 2025 [1] Package Offerings - Dentrix Ascend now offers three structured packages: Ascend Accelerate, Ascend Pro, and Ascend Essentials, each designed to cater to different organizational needs and scalability [1] - Ascend Accelerate is tailored for multi-location organizations, while Ascend Pro is for established practices seeking automation, and Ascend Essentials is aimed at new or smaller practices [1] Support and Implementation - The new era of Dentrix Ascend includes AI-powered support through Claire, providing 24/7 assistance and facilitating smooth migration for practices and DSOs [1] - This support aims to help organizations realize value quickly and manage complexity as they scale [1] Market Position - Dentrix and Dentrix Ascend currently serve over 48,000 practices in the U.S. and 90% of the top 50 DSOs, processing approximately 100 million claims annually [1] - The advancements in Dentrix Ascend strengthen its position as a leading platform for modern dental organizations [1]

Summary of Henry Schein Conference Call Company Overview - **Company**: Henry Schein - **Industry**: Healthcare distribution, specifically dental and medical supplies Key Points and Arguments Leadership Transition - Henry Schein has appointed Fred Lowery as the new CEO, marking the first leadership change since the first Bush administration, with Lowery being the fourth CEO in 94 years [2][3] - Lowery brings operational excellence and a fresh perspective, previously having a successful tenure at Thermo Fisher [3][4] Market Trends - The dental market shows signs of stabilization and potential improvement, with core dental market growth previously estimated at 2%-4% [6][7] - Henry Schein's sales growth in the fourth quarter exceeded market growth, attributed to aggressive customer relationship strategies and promotional partnerships [7][8] Equipment Sales - The equipment segment saw significant growth, driven by partnerships with manufacturers and exclusive promotions [8][12] - Growth in equipment sales is viewed as a bellwether for practitioners' confidence in investing in their practices, indicating potential expansion in dental services [12][13] Macro Economic Factors - Interest rates have some influence on equipment sales, but the correlation is not strong; access to care and unemployment rates are more critical indicators for market performance [15][16] - The company focuses on helping practices improve efficiency and patient throughput rather than solely discussing macroeconomic indicators with clients [16] Role of Dental Service Organizations (DSOs) - DSOs are crucial for both merchandise and equipment sales, with 25 of the 27 largest DSOs in the U.S. considering Henry Schein their primary distributor [19] - The growth of DSOs is outpacing the rest of the market, providing Henry Schein with opportunities to capture market share [19] Specialty Segment Growth - Henry Schein is positioned as a leading player in the implant and endodontic markets, with steady growth in these segments [28][30] - The company aims to expand its market share in implants, particularly through value implants that appeal to general practitioners [29][35] Technology and AI Integration - Henry Schein One is leveraging AI through a partnership with AWS to enhance its digital imaging and practice management solutions [37][38] - New products like Voice Notes and Image Verify aim to reduce administrative burdens and improve operational efficiency for practitioners [38][39] Value Creation Plan - The company is focused on a value creation plan expected to deliver $125 million in operating income improvement by the end of 2026 [47][48] - This plan emphasizes structural changes and resource optimization across the organization, differing from past grassroots restructuring efforts [52] Medical Business Expansion - Henry Schein is expanding its medical business, particularly in home healthcare, which is growing faster and more profitably than its core medical business [56] - The company is focusing on consumable merchandise rather than durable medical equipment (DME) for its Home Solutions business [58] Additional Important Insights - The company is committed to maintaining strategic relationships with DSOs to avoid transactional dynamics and focus on driving profitability for practices [23][24] - The specialty segment, particularly implants, is seen as a significant growth area, with a goal of increasing the contribution of high-margin products to over 50% of operating income by 2027 [34][35]

Executive Narrative - Henry Schein, Inc. achieved the highest sales growth in 15 quarters, driven by the effective execution of the BOLD+1 strategic plan and recovery from previous cybersecurity disruptions [4] - High-growth, high-margin businesses now account for nearly 50% of total operating income, indicating a strategic shift towards specialty products and technology solutions [4] - Global dental equipment sales reached record levels, with double-digit growth in traditional equipment and market share gains from technical service capabilities [4] Sales and Market Performance - U.S. dental merchandise growth was supported by data-driven marketing initiatives and increased procedure volumes, as indicated by Henry Schein One eClaims activity [4] - The Global Technology segment saw a 20% year-over-year increase in cloud-based subscribers, exceeding 11,000 Dentrix Ascend users globally [4] Strategic Initiatives - Strategic partnerships with Amazon Web Services are integrating generative and agentic AI into practice management systems to automate administrative workflows and clinical documentation [4] - Management attributes recent success to a shift from internal recovery efforts back to aggressive market engagement and sales force expansion [4] Future Projections - Sales growth for 2026 is projected at 3% to 5%, assuming stable dental and medical end markets and consistent foreign currency exchange rates [4] - Earnings growth is expected to be more heavily weighted towards the second half of 2026 as value creation initiatives reach full implementation [4] - Value creation projects are targeted to deliver over $125 million in annual run-rate operating income improvement by the end of 2026 [4] E-commerce and Restructuring - The rollout of the new henryschein.com e-commerce platform is scheduled for completion for U.S. dental and Canadian customers in Q1 2026 [4] - The company recorded $105 million in total restructuring expenses for the full year 2025 related to the program announced in August 2024 [4] Market Challenges - U.S. medical sales face headwinds from lower comparative demand in respiratory products and vaccinations following post-pandemic normalization [6] - Management indicated that potential tariff impacts can be mitigated through alternative sourcing and passing costs through to customers [6]

Core Insights - Henry Schein reported its highest sales growth in 15 quarters, with fourth-quarter global sales reaching $3.4 billion, up 7.7% year over year, driven by strong performance across various segments [2][4][6]. Financial Performance - The company reported a fourth-quarter GAAP operating margin of 4.76%, down 10 basis points from the prior year, while the non-GAAP operating margin was 7.42%, remaining relatively flat year over year [1]. - Fourth-quarter GAAP net income was $101 million, or $0.85 per diluted share, compared to $94 million, or $0.74 per diluted share, in the prior-year period. Non-GAAP net income was $160 million, or $1.34 per diluted share, up from $149 million, or $1.19 per diluted share [7]. - Adjusted EBITDA for the fourth quarter was $291 million, an increase from $270 million, representing an 8.4% growth [7]. Segment Performance - Global specialty products saw sales growth of 14.6%, driven by strong performance in implants and biomaterials, with double-digit growth in value implants [10]. - Global technology sales grew 8.4%, supported by practice management software and significant growth in Dentrix Ascend, which surpassed 11,000 subscribers [11]. - The global distribution and value-added services group delivered 7.0% sales growth, with U.S. dental merchandise sales growing by 3.6% and U.S. dental equipment sales growing by 10.6% [8][9]. Leadership Transition - Fred Lowery will officially join as CEO next week, with a focus on a 100-day "listening tour" to validate existing initiatives and engage with stakeholders [3][6]. - Stanley Bergman will remain as Chairman of the Board, emphasizing Lowery's experience in scaling businesses through acquisitions and organic growth [4][6]. Strategic Initiatives - The company expects over $200 million of operating income improvement through cost savings and incremental gross margin opportunities, with an annual run-rate improvement of over $125 million by the end of 2026 [13]. - Henry Schein repurchased 2.8 million shares for $200 million at an average price of $71.10 per share, ending the year with approximately $780 million remaining under its authorization [14]. 2026 Outlook - For 2026, Henry Schein guided to sales growth of 3% to 5% and non-GAAP diluted EPS of $5.23 to $5.37, representing 5% to 8% growth compared to 2025 [15]. - The guidance assumes stable dental and medical end markets and consistent foreign exchange rates [15][16].

Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [29] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the prior year [30] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30] - Non-GAAP net income for Q4 2025 was $160 million or $1.34 per diluted share, compared to $149 million or $1.19 per diluted share in the prior year [31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - Global specialty products group sales grew by 14.6%, driven by strong performance in implants and biomaterials [33] - Global technology group sales grew by 8.4%, with significant contributions from practice management software [33] Market Data and Key Metrics Changes - U.S. dental merchandise sales growth reflected continued market share gains, with January 2026 sales showing good momentum [18] - International dental merchandise sales grew by 9.2% in constant currencies, with strong growth across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - U.S. medical distribution sales grew by 4.9%, reflecting strong growth in home solutions, while international dental equipment sales grew by 13.9% [32][33] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [12][13] - The rollout of the global e-commerce platform, henryschein.com, is underway, with expectations to complete the rollout to U.S. Dental and Canadian customers in Q1 2026 [14] - The company is focusing on innovative solutions to enhance patient care and operational efficiency, including partnerships with Amazon Web Services for AI integration [14][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the U.S. dental market, with positive trends in patient traffic and dentist investments in technology [51][54] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to ongoing value creation initiatives [58] - Management noted that the international dental equipment market is performing well, with broad-based growth across many countries [23][32] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [35] - Operating cash flow for Q4 2025 was $381 million, compared to $204 million in Q4 2024, driven by working capital management [36] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from value creation initiatives will be more heavily weighted to the back half of the year, with some lumpiness expected in the first half [43][44] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases [46][48] Question: Durability of dental market performance - Management confirmed that the U.S. dental market is stable and leaning positively, with good feelings among dentists regarding investments in technology [50][54] Question: Sustainability of implant performance - Management expressed optimism about the implant market, particularly in Europe, while noting that U.S. growth is currently less than 5% [72][73]

Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [29][30] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the previous year [30] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30][31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - Global specialty products group sales grew by 14.6%, driven by strong performance in implants and biomaterials, with double-digit growth in value implants [33][24] - Global technology group sales increased by 8.4%, with significant growth in practice management software, particularly Dentrix Ascend [33][26] Market Data and Key Metrics Changes - International dental merchandise sales grew by 9.2%, with strong performance across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - U.S. medical distribution sales grew by 4.9%, reflecting strong demand in home solutions, although respiratory product demand decreased [21][22] - International dental equipment sales grew by 13.9%, with broad-based growth across many countries and equipment categories [32][23] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [12] - The rollout of the global e-commerce platform, henryschein.com, is underway, with expectations to complete the rollout to U.S. Dental and Canadian customers in Q1 2026 [13] - The company is focusing on innovative solutions to enhance patient care and operational efficiency, including partnerships with Amazon Web Services for AI integration [14][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability and positive trends in the U.S. dental market, with indications of increased patient traffic and investment in technology by dentists [52][54] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to ongoing value creation initiatives [58] - Management noted that the market is stable, with positive sentiment among dentists regarding investments in new technologies [52][54] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [36] - The effective tax rate for Q4 2025 on a non-GAAP basis was 22.7%, compared to 22% for Q4 2024 [30] - The company expects 2026 sales growth to be in the range of 3%-5% over 2025, with non-GAAP diluted EPS projected to be between $5.23 and $5.37 [38] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from value creation initiatives will be more heavily weighted to the back half of the year, with some lumpiness expected in the first half [44][58] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases [47][49] Question: Durability of dental market performance - Management confirmed that the dental market is stable and leaning positively, with good feelings among dentists about investing in technology [52][54] Question: Sustainability of implant performance - Management expressed optimism about the implant market, particularly in Europe, while noting that U.S. growth is more stable but not as robust [70][72]

Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [28][29] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the prior year [29] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30] - Non-GAAP net income for Q4 2025 was $160 million or $1.34 per diluted share, compared to $149 million or $1.19 per diluted share in the prior year [31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - International dental merchandise sales grew by 9.2%, driven by growth across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - Global specialty products group sales increased by 14.6%, with strong performance in implants and biomaterials, particularly in Germany, Brazil, and France [22][33] Market Data and Key Metrics Changes - U.S. medical distribution sales grew by 4.9%, reflecting strong growth in home solutions, while international dental equipment sales grew by 13.9% [32][33] - The U.S. dental market showed signs of stability and positive trends, with patient traffic remaining stable and a slight positive lean observed [15][51] - International equipment sales growth was broad-based, benefiting from currency exchange rates [21] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [11] - Significant progress has been made in rolling out the global e-commerce platform, henryschein.com, and partnerships with Amazon Web Services for AI integration [12][26] - The company aims to achieve over $200 million in operating income improvement through value creation initiatives, including cost savings and capturing incremental gross margin opportunities [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the U.S. dental market and the positive sentiment among dentists regarding investments in new technologies [51] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to the timing of value creation initiatives [58] - Management noted that the overall market for dental implants is stable, with positive momentum in international markets, particularly in Germany [72] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [35] - Operating cash flow for Q4 2025 was $381 million, compared to $204 million in Q4 2024, driven by effective working capital management [36] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from the $125 million run rate will be more heavily weighted to the back half of the year, with some lumpiness expected in the quarters [41][42] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases observed [45][48] Question: Durability of market performance - Management confirmed that the U.S. dental market is stable and leaning positively, with good feelings among dentists about investing in new technologies [50][51] Question: Sustainability of implant performance - Management expressed optimism about the sustainability of implant performance, particularly in international markets, while noting that U.S. growth is more stable but less robust [67][72]

Q4 2025 Earnings Conference Call Financial Results & Outlook February 24, 2026 1 Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied here ...

Core Insights - Henry Schein One has launched AI-driven Image Verify, enhancing its dental practice management systems [1] - This innovation is part of a series of product advancements aimed at achieving a "Clean Claims" vision in dentistry [1] - Image Verify is integrated into Dentrix and Dentrix Ascend, streamlining the claims submission process for dental practices [1]